By notice dated February 4, 2004, and published in the
The firm plans to manufacture the controlled substances for formulation into pharmaceutical products.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Norac Corporation to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has investigated Norac Corporation to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to Title 21 United States Code 823 and Title 28 Code of Federal Regulations 0.100 and 0.104, the above firm is granted registration as a bulk manufacturer of the basic class(es) of controlled substance(s) listed.